|
KMID : 0360319920240040562
|
|
Journal of Korean Cancer Research Association
1992 Volume.24 No. 4 p.562 ~ p.569
|
|
|
Etoposide, Adriamycin, Cisplatin(EAP) Combination Chemotherapy for Advanced Gastric Cancer
|
|
김준식
김정희/어완규/김시영/윤휘중/조경삼
|
|
|
Abstract
|
|
|
Recently, Etoposide, Adriamycin and Cisplatin(EAP) combination chemotherapy is widely used in patients with advanced gastric cancer. Response rates of more than 50% were reported with this combination by Preusser.
Forty-one patients with metastatic or nonresectable gastric cancer received etoposide, 10mg/m* IV, day4-6; adriamycin, 20mg/m* IV, days 1 and 7; cisplatin, 40mg/m* IV, days 2 and 8. Cycles were repeated every 4 weeks. Response rate, survival rate
and
toxicity were evaluated.
@ES Results were as following;
@EN 1) the total 41 patients received EAP chemotherapy. Twenty-four patients were evaluated. The eighty eight cycles of chemotherapy were administered(mean, 3.7 cycles per patient; range, 2-8 cycles)
2) Of the sixteen patients with measurable disease, none had complete remission and 3(18.8%) achieved parital remission, resulting in an overall response rate of 18.8%. There were seven stable disease and six progressive disease.
3) The overall median survival was 25 weeks(7-68 wks) and the median time to progression was 16 weeks.
4) Main toxicities were leukopenia and thrombocytopenia. 16% of patients developed grade 3 to 4 myelosuppression and 4% developed severe infections. Nonhematologic toxicites such as nausea, vomiting and alopecia appear in all cases, but
toxicities
of
WHO grade 4 were not observed. Neurologic toxicity and renal insufficiency. Who grade 1 were observed in 37% and 17% of patients.
In view of this low response rate, low survival rate and toxicity, this combination as a palliative therapy of advanced gastric cancer is not justified.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|